Nuvation Bio Inc. (NUVB) FY2026 Q2 P&L / Income Statement

Nuvation Bio Inc. (NUVB) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (Revenue Recognition (Additional Information)). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

31,687,000 US dollars

Total costs and expenses

82,723,000 US dollars

Loss from operations

negative 51,036,000 US dollars

Total other (expense) income, net

negative 11,804,000 US dollars

Income (loss) before income taxes

negative 62,840,000 US dollars

Provision for income taxes

0 US dollars

Net loss

negative 62,840,000 US dollars

Product Revenue

23,200,000 US dollars

License

8,495,000 US dollars

Total costs and expenses

82,723,000 US dollars

Revenue before reconciliation (calculated)

31,695,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Components above reported revenue (calculated)

negative 8,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.